A Randomized, Double-Blind, Dose-Escalating, Placebo-controlled Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
Latest Information Update: 30 Aug 2025
At a glance
- Drugs SHR 1139 (Primary) ; SHR 1139 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 14 Jul 2025 New trial record